Indications for: TAKHZYRO
Prophylaxis to prevent attacks of hereditary angioedema (HAE).
Give by SC inj into abdomen, thigh, or upper arm. Initially 300mg every 2 weeks. May consider 300mg every 4 weeks if well-controlled (eg, attack free) for >6 months.
<12yrs: not established.
Discontinue and treat if severe hypersensitivity reaction occurs. Pregnancy (during 3rd trimester). Nursing mothers.
Plasma kallikrein inhibitor.
May increase activated partial thromboplastin time (aPTT) on assay.
Inj site reactions, upper respiratory infections, headache, rash, myalgia, dizziness, diarrhea; hypersensitivity, increased AST/ALT.
Generic Drug Availability:
Single-dose vial—1; single-dose prefilled syringe—1 (w. needle)